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Although caused by vastly different pathogens, the world’s three most serious infectious diseases,
tuberculosis, malaria, and HIV-1 infection, share the common problem of drug resistance. The pace
of drug development has been very slow for tuberculosis and malaria and rapid for HIV-1. But for
each disease, resistance to most drugs has appeared quickly after the introduction of the drug.
Learning how to manage and prevent resistance is a major medical challenge that requires an
understanding of the evolutionary dynamics of each pathogen. This Review summarizes the simi-
larities and differences in the evolution of drug resistance for these three pathogens.Introduction
Tuberculosis (TB), malaria, and HIV are the Big Three infectious
diseases worldwide. Together, they cause 5 million deaths/
year and substantially affect the lives of a billion more people.
The etiologic agents (Mycobacterium tuberculosis, Plasmodium
species, and HIV-1) come from vastly different parts of the tree of
life (viruses do not fit on the tree) and yet have much in common.
Chief on the list of similarities is drug resistance. The evolution of
resistant variants has made some TB infections virtually untreat-
able, threatens to make malaria untreatable, and has necessi-
tated complex combination therapy to control HIV-1 infection.
This Review describes common themes and interesting differ-
ences emerging from a consideration of the resistance mecha-
nisms, evolutionary dynamics, and persistence of these agents
(Table 1). Beyond their commonalities with respect to drug resis-
tance, these diseases are inextricably intertwined at a population
level. The three infections are all widespread in the developing
world, and coinfections are common. HIV-1 infection predis-
poses to increased severity of TB and malaria. Interactions
between the agents used to treat these diseases are complex.
Considering these diseases together may yield lessons that will
cross from one organism to another and will help combat all
three scourges in synergistic fashion.
Tuberculosis
A century ago, a diagnosis of pulmonary consumption was
considered a death sentence. For individuals infected with the
bacterial pathogen Mycobacterium tuberculosis (Mtb), the only
known cure was a regimen of rest, fresh air, sunshine, and a
hearty diet. This approach remained the standard of care until
the mid 1900s, when antitubercular drugs were introduced.
Recently, the growing problem of drug-resistant TB has threat-
ened to return us to a time when this diagnosis was a death sen-
tence. Multidrug-resistant TB strains (MDR-TB) cause 3.6% ofTB cases and require at least 2 years of treatment with as
many as six potentially toxic drugs (WHO, 2010). Extensively
drug-resistant strains (XDR-TB), whichmay be nearly impossible
to cure, have been isolated in all countries that have adequate
diagnostic capability to recognize them. A concerted effort on
many fronts, as outlined in the thought-provoking Review by
Gandhi et al. (2010), will be necessary to confront this challenge.
The Central Problem of Tuberculosis: The Unceasing
March to Resistance
Development of resistance to antibiotics is common in many
bacterial infections. Resistance is often due to transmission of
infrequently arising resistant clones, generated throughmutation
or acquisition of resistance gene-bearing mobile genetic
elements. The week or two of treatment required to clear most
bacterial infections is typically insufficient to cause the de novo
generation of resistance. However, cure of an uncomplicated
TB infection requires at least 6 months on up to four different
drugs, allowing the bacteria ample opportunity to develop
resistance.
The first antitubercular drug was streptomycin (STR), shown
by Schatz in 1944 to have antitubercular activity (Schatz and
Waksman, 1944) and demonstrated in 1946 to have substantial
activity in human patients (Hinshaw et al., 1946). Alarmingly,
the evolution of resistance in over 85% of cases was reported
shortly thereafter (BMRC, 1948). Streptomycin targets bacterial
protein synthesis, and mutations in the 16S ribosomal DNA
(rrs) and the S12 ribosomal protein gene (rpsL) can cause resis-
tance (Figure 1). Para-aminosalicylic acid (PAS) was widely
introduced in 1946 (Lehmann, 1946), and reports of resistance
appeared in 1949 (Sweany et al., 1949; Dunner et al., 1949).
Resistance mutations map to genes involved in folate and
salicylate metabolism (Mathys et al., 2009).
In an advance that ultimately contributed to the success
of HIV-1 treatment, PAS and STR were used together inCell 148, March 16, 2012 ª2012 Elsevier Inc. 1271
Table 1. Similarities and Differences in Drug Resistance
Tuberculosis Malaria HIV
Causative Agent
Name Mycobacterium tuberculosis five Plasmodium species HIV-1
Type of organism mycobacterium protozoal parasite retrovirus
Number of genes 4,400 >5,000 9
Drugs
Available agents old and limited old and limited >25 drugs from 6 classes
Regimens four-drug combination single agents or artemesinin
combination therapy
three-drug combinations
Required length
of treatment
at least 6 months, 2 years
or more in some cases
a few days lifelong
Efficacy high for sensitive strains
in adherent patients,
low for resistant strains
high for most regimens,
influenced by Hill slope?
influenced by Hill slope,
very high for combinations
but not curative
Resistance
Extent seen for all drugs seen for all drugs except
possibly artemisinin
seen for all drugs
Principal mode of acquisition de novo and transmitted transmitted de novo and transmitted
Molecular mechanisms target and activator mutations target mutations,
drug transporters
target mutations
Multidrug resistance MDR and XDR-TB,
serious problem
MDR a problem in
regional pockets
serious problem, successful
salvage Rx with newer regimens
Evolutionary Dynamics
Population size 1010 or greater huge at intraerythrocytic stage large
Mutation rate 106–1010/ generation 106–109/generation 0.33/generation
Generation time 18–24 hr doubles in 12 hr in red blood cells,
R0 = 10–16
2 days, R0 = 20
Special mechanisms established a life-long
chronic infection
genome plasticity, accelerated
resistance to multiple drugs,
mutagenic drugs (atovaquone)
evolution of a new
enzymatic activity
(excision of AZT)
Persistence
Persistence in treated patients persisters dormant parasites? latencycombination therapy that delayed the emergence of resistance
(Dunner et al., 1949; BMRC, 1950). Combination therapy
became standard and was expanded in 1952 with the inclusion
of isoniazid (INH) (BMRC, 1952). The target of isoniazid is InhA,
which catalyzes a critical step in the synthesis of mycolic acids
that comprise theMtb cell wall (Vilche`ze et al., 2006). Mutations
in inhA and the gene encoding the activator of INH, katG, as well
as ndh and mshB cause resistance (Vilche`ze et al., 2006; Vil-
che`ze and Jacobs, 2007). Although this triple combination of
STR+PAS+INH was successful in treating patients, in retrospect
it was a decisive blow to support for TB research, as the problem
was considered ‘‘solved.’’ Combination therapy was further
improved when ethambutol (EMB), discovered in 1961, quickly
replaced PAS (Thomas et al., 1961; Ahmad et al., 2011). It inter-
feres with cell-wall biosynthesis (Takayama and Kilburn, 1989),
and mutations mapping to embB, an arabinosyl transferase,
can result in resistance (Sreevatsan et al., 1997).
In 1972, two additional drugs were adopted into the standard
therapy, relegating the injectable STR to second-line status
and reducing treatment from 18 to 6 months (EA/BMRC, 1972;1272 Cell 148, March 16, 2012 ª2012 Elsevier Inc.Ahmad et al., 2011). Rifampicin (RIF), an inhibitor of transcription
(resistance mutations map to the RNA polymerase subunit gene
rpoB), and pyrazinamide (PZA) complete the current quartet
(Yeager et al., 1952). Mutations in pncA, the gene encoding the
activator of PZA, and rpsA, which encodes a ribosomal protein,
result in PZA resistance (Shi et al., 2011). However, the target
and mechanism of PZA remain controversial (Zimhony et al.,
2000). The current first-line combination of INH+RIF+PZA+EMB
allows short-course treatment: 2 months with all four drugs
followed by 4 months of INH+RIF (EA/BMRC, 1972). This
regimen has not changed in nearly 40 years because despite
substantial drawbacks of length, complexity, and toxicity, it is
efficacious in the treatment of drug-sensitive TB in adherent
patients. Lack of adherence with lengthy treatment is common
as patients often abandon therapywhen they begin to feel better,
allowing the emergence of resistance.
Unfortunately, recent research has shown that the standard
four-drug therapy results in drug resistance in immune-deficient
mice, a finding with serious implications for the treatment of
immunocompromised individuals such as those with AIDS
Figure 1. Antitubercular Drugs and Their
Targets
Standard ‘‘short-course’’ tuberculosis chemo-
therapy consists of 2 months of treatment with
rifampicin, isoniazid, pyrazinamide, and etham-
butol followed by four months on rifampicin and
isoniazid. The targets of each member of the
first-line quartet have been identified except for
pyrazinamide, whose mechanism remains con-
troversial. Drugs such as isoniazid, rifampicin, and
the fluoroquinolones require active bacterial
replication for activity, whereas pyrazinamide, ni-
troimidazoles, and TMC207 may be active against
dormant bacilli.(Zhang et al., 2011). Other problems with the regimen have been
reported. Unfavorable interactions between different TB drugs
can occur (Dickinson et al., 1977; Grosset et al., 1992; Almeida
et al., 2009), and for those coinfected with TB and HIV-1, interfer-
ence with the efficacy of HIV-1 antiretrovirals has been shown
(Centers for Disease Control and Prevention, 1996). Pharmaco-
kinetic studies suggest that combined dosingmay leave patients
with suboptimal plasma concentrations of individual drugs at
several times during the day. Fortunately, a recent study has
shown that this type of dosingmay actually result in better bacte-
rial clearance, possibly due to prevention of antagonism, and
does not seem to encourage resistance (Srivastava et al.,
2011). Combination therapy is clearly indispensible to treating
TB and preventing resistance. However, the current standard
therapy may not be optimal.
Second-line drugs for MDR-TB include fluoroquinolones,
which target DNA gyrase, ethionamide (ETH), which like INH
targets mycolic acid biosynthesis, aminoglycosides such as
kanamycin and peptides such as capreomycin, which target
the ribosome, and the peptidoglycan crosslinking inhibitor
D-cycloserine (Johnson et al., 2006) (Figure 1). Like the first-
line drugs, resistance to second-line drugs is chromosomally
encoded and has not been shown to be transferred by mobile
genetic elements. Initially, this gave researchers hope that
multiple resistances would need to arise within a single clone
and be slow to spread, but with recent reports of transmission
of multidrug-resistant strains, it appears that the clonal structureCell 148of bacterial populations will offer little
protection against the spread of drug
resistance (Andrews et al., 2008).
Tolerance and Persistence: The
‘‘Hunkered-down’’ Phenotype
Apart from the problem of drug resis-
tance, but possibly contributing to it, is
the phenomenon of drug tolerance. Why
does it take 6 months to treat drug-sensi-
tive TB when even the most recalcitrant
of other bacterial infections can be
successfully treated in a couple weeks?
The long, complex treatment regimen
is necessitated by the ability of the
bacteria to enter a state in which they
are unaffected by or recalcitrant to drugs.
Actively growing Mtb cells must undergoa developmental transition to a ‘‘hunkered-down’’ phenotype to
survive in the face of drug and immune pressure. A typical
immune response is capable of containing the infection in a
chronic state, with balanced bacterial growth and killing (Ford
et al., 2011; Gill et al., 2009). Drug intervention is necessary to
upset this equilibrium in favor of bacterial clearance. In this war
of attrition between the bacteria and the combined effects of
immunologic and pharmacologic interventions,Mtb has evolved
to persist by altering its metabolism and possibly slowing its
replication. This is exemplified by experiments in which infected
animals were treatedwith antibiotics for up to 6months, resulting
in the lack of culturable bacteria from any organ. Upon cessation
of treatment, some infections spontaneously reactivated
(McCune et al., 1956; McCune and Tompsett, 1956). This
number increased dramatically when the animals were immuno-
suppressed by treatment with corticosteroids (McCune et al.,
1966).
As the importance of eradicating persisters has been realized,
efforts to develop drugs targeting them have increased.
TMC207, a recently discovered inhibitor of the F0/F1 ATP syn-
thase, is active against nonreplicating Mtb (Andries et al.,
2005; Koul et al., 2008). It is now in phase IIb clinical trials. Recent
work has shown that the mycobacterial proteasome is neces-
sary for surviving nitrooxidative stress and persistence during
chronic infection. Specific inhibitors that spare the human pro-
teasome have been identified (Darwin et al., 2003; Gandotra
et al., 2007; Lin et al., 2009). Also, recent studies (Adams et al.,, March 16, 2012 ª2012 Elsevier Inc. 1273
Figure 2. Plasmodium Life Cycle
Depicted are different stages. Red, intraerythro-
cytic stages; yellow, mosquito stages; brown, liver
stages. PM/SX, pyrimethamine/sulphadoxine;
ATOV/PG, atovaquone/proguanil; CQ/Q, 4-ami-
noquinolines like chloroquine and quinine and
related compounds; ART, artemesinin and related
compounds; TCN, tetracyclines; PQ, primaquine.2011; Srivastava et al., 2010) demonstrate the importance of
efflux mechanisms to drug tolerance in actively dividing cells
and suggest that targeting efflux may be a useful strategy to
prevent the emergence of resistance.
The Current State of Tuberculosis Chemotherapy
and Future Directions
The anti-TB arsenal of drugs is decades old and is being quickly
depleted due to resistance. Although it is obvious that we need
new bactericidal antibiotics with novel mechanisms of action
that kill replicating and nonreplicating bacteria, resulting in over-
all treatment shortening, it is imperative that future drug develop-
ment address a number of other factors. Foremost among these
is activity against MDR and XDR strains. One approach is to re-
purpose existing drugs approved for other infections, such as
the MRSA drug linezolid and the antibiotic metronidazole, both
currently in phase II trials. Much effort is also focused on creating
novel inhibitors of the well-validated targets, such as InhA (target
of INH) and RpoB (target of RIF). A small number of drugs, such
as TMC207, PA824, and OPC67683, with novel targets are
currently in phase II clinical trials, and SQ109 and LL-3858 are
both in phase I trials (Spigelman, 2007). Even for these drugs,
with new modes of action, resistance develops in vitro at rates
similar to the those for existing drugs, if not more quickly (Kaneko
et al., 2011).
To design more effective drugs, we need a better under-
standing of the basis of mycobacterial growth in vivo and the
mechanism by which the bacterium achieves the developmental
shift that allows persistent infection and drug tolerance. New1274 Cell 148, March 16, 2012 ª2012 Elsevier Inc.research on genes essential for Mtb
survival in the host has prompted the
search for inhibitors of the products of
these attractive targets. Drug develop-
ment processes also need a paradigm
shift. Current approaches typically in-
volve phenotypic screening of libraries
against M. smegmatis or M. bovis. Auxo-
trophic strains of Mtb that are safe and
more closely related to the target bacte-
rium may prove more suitable for high-
throughput screening (Sambandamurthy
et al., 2002), Moreover, auxotrophic
strains of drug-resistant Mtb could be
used. New animal models that exhibit
more human like-pathology would greatly
improve the chances of new drugs pro-
gressing to human trials (Pichugin et al.,
2009; Gil et al., 2010).
Although encouraging, these develop-
ments are still starkly minimal in the faceof the enormous challenge of the explosion of drug-resistant
TB and the collision of the HIV-1 and TB epidemics. As with
HIV-1, it is becoming increasingly clear that no single drug can
act as a magic bullet against TB. In this context it is essential
to develop new drug combinations and consider these to be
the unit of development rather than individual drugs (Ginsberg,
2011).
Malaria
Resistance to almost every drug used to treat malaria has devel-
oped, including drugs acting at different stages in the complex
life cycle of this parasite (Figure 2). The only possible exception
is artemisinin. Chloroquine, once a mainstay of prophylaxis and
treatment, has become obsolete in most areas where malaria is
endemic. Newer treatments have also failed. As with TB and
HIV-1, resistance to some drugs has been documented almost
simultaneously with drug introduction (Hyde, 2005). The rate at
which resistance develops depends on the mutation rate, the
number of mutations needed to confer resistance, the use and
abuse of the antimalarial drug, and pharmacokinetic/pharmaco-
dynamic considerations (White, 2004). As with TB, our current
antimalarial armementarium is thin and consists of drugs that
are expensive and/or toxic and that are starting to fail. We
have already run out of options to protect certain subpopula-
tions, such as women in the first trimester of pregnancy.
Artemesinin derivatives are widely used in endemic areas, and
resistance is a major concern. Evidence for artemesinin resis-
tance is not yet compelling. Certain populations are now taking
longer to clear parasites from the bloodstream than was histori-
cally the case, but in culture these organisms do not have
detectable resistance (Dondorp et al., 2009). Because existing
combination regimens (artemesinin combination therapy or
ACT) and late-stage drug development projects depend on
these agents, we will have a therapeutic crisis if artemesinin
resistance continues to emerge. There is an urgent need for
new antimalarial agents and new strategies for overcoming
resistance.
Types of Resistance
Resistance occurs via mechanisms that are well known in other
organisms. Resistance to enzyme inhibitors often is due to target
mutation. Usually more than a single mutation is needed to
confer clinically significant resistance. Resistance to drugs that
cause nonspecific cellular damage (4-aminoquinolines, arteme-
sinins) is typically through amplification and/or mutation of
multidrug resistance (MDR) and MDR-related protein (MRP)
transporters that pump the agent out of its site of action (Koen-
derink et al., 2010). In the case of one 4-aminoquinoline, chloro-
quine, the parasite has no transporter that can efficiently
eliminate the drug from its site of action, the food vacuole. The
parasite has had to make one by extensive mutagenesis of a
putative peptide transporter in the food vacuole, called
P. falciparum chloroquine-resistance transporter or PfCRT
(Bray et al., 2005). The mutations allow PfCRT to maintain its
normal cellular function while now facilitating recognition and
efflux of chloroquine from the food vacuole (Martin et al.,
2009). Interestingly, although this mechanism of resistance has
arisen independently in P. falciparum in different regions of the
world, chloroquine resistance in P. vivax does not involve PvCRT
(P. vivax chloroquine-resistance transporter) (Nomura et al.,
2001), and its basis remains unknown.
Mechanisms for Generating Resistance
The point mutation rate in P. falciparum is 106 to 109/genera-
tion (Rathod, 1997; Cooper et al., 2002; Istvan et al., 2011). Given
that an infected person may have 1010 to 1013 parasites in the
bloodstream, and that there are an estimated 5 3 108 infections
per year, there are on the order of 1020 parasites in the world
each year (Rathod, 1997). It follows that any particular triple-
mutant parasite has a substantial chance of existing at some
time somewhere in the world. Thus the sheer numbers involved
represent a powerful force for the generation of resistance. Copy
number variation is also readily achieved; such events occur
easily in culture, and evidence for frequent amplification and
deletion events is apparent in the genome (Anderson et al.,
2009). Compounding genomic plasticity is a phenomenon
known as ARMD (accelerated resistance to multiple drugs).
Certain P. falciparum strains have up to 10003 higher frequency
of resistance to selected compounds (Rathod, 1997). The
molecular basis of ARMD is uncertain. These strains respond
to drug challenge by generating multiple mutations in a random
region of the genome. The concept is that if these mutations
affect a gene in a way that leads to resistance, that parasite
(and therefore its lineage) can survive. In this context, it is of
interest that chloroquine-resistant parasites have evidence of
extensive mutations in and around the CRT gene (Fidock et al.,
2000), some of which are important for conferring resistance. A
final mechanism involves drugs whose effects are mutagenic,thereby increasing the frequency of resistance. Atovaquone
is a mitochondrial cytochrome inhibitor that is potent against
malaria parasites. Resistance to atovaquone as a single agent
develops easily. Blockade of electron transport leads to accu-
mulation of electrons and superoxide, which promotes mutation
of the mitochondrial DNA, increasing the frequency of resistance
(Vaidya and Mather, 2000).
Pharmacokinetics also play a role in the generation of resis-
tance. Some antimalarials (many quinolines) have prolonged
half-lives. New infections that arise weeks after a prophylactic
dose or a treatment course will expose parasites to subthera-
peutic drug concentrations that could select for resistance
(White, 2004). Although the parasite pool that could harbor
mutation upon initial emergence from the liver is relatively
low (about 100,000), the possibility of selecting a resistant
mutant is significant, and the probability of enriching resistant
parasites from a pre-existing mixed population is high. In the
case of intermittent preventive treatment in pregnancy, women
treated with sulfadoxine-pyramethamine had higher overall
parasitemias, suggesting a competitive facilitation of the re-
sistant parasites (Harrington et al., 2009). Treating patients
who are coinfected with HIV-1 and malaria also has the potential
to engender resistant malaria parasites. Trimethoprim-sulfa,
used as prophylaxis against opportunistic infections in patients
with HIV-1, and HIV-1 protease inhibitors both have antimalarial
activity.
Evolutionary Dynamics
Resistance to each antimalarial agent has its own evolutionary
history, which is still being written. The evolution of resistance
has been studied in most detail for chloroquine and the antifo-
lates. Chloroquine was introduced in the 1940s, and resistance
was first documented in the 1960s. At least two independent
foci of resistance developed in Southeast Asia and South Amer-
ica. Resistance spread from Asia to Africa and from east to west
across the African continent (Payne, 1987). There appears to be
a fitness defect in resistant mutants, and in regions where chlo-
roquine has been withdrawn, sensitive parasites have taken over
(Laufer et al., 2006).
The dihydrofolate reductase (DHFR) inhibitor pyrimethamine
was introduced in the 1950s, and resistance was detected
almost immediately. The synergistic dihydropteroate synthetase
(DHPS) inhibitor sulphadoxine was added, and the combination
(SP) was successfully used for decades (Mu¨ller and Hyde, 2010).
DHPS-resistant parasites and SP failure were documented in the
early 1990s. Double DHPSmutations combined with triple DHFR
mutations confer high-level SP resistance and early treatment
failure. Resistance appears to have originated in Southeast
Asia and spread through Africa in a pattern similar to that of
chloroquine. Interestingly, despite the ease of selecting resis-
tance to these drugs in the laboratory, molecular epidemiology
suggests a single origin and a sweep of the resistant parasite
across Africa (Roper et al., 2003), although there is evidence
for some independent origins of sulphadoxine resistance
(Vinayak et al., 2010).
Persistence
Reinfection is common in malaria, especially in hyperendemic
regions, because immunity from previous infection is partial at
best. Relapse is common with P. vivax and ovale, stemmingCell 148, March 16, 2012 ª2012 Elsevier Inc. 1275
from dormant liver forms (hypnozoites) that can activate years
later. Recrudescence of P. falciparum after apparently effective
drug treatment is a phenomenon seen with artemesinin. Arteme-
sinin and its derivatives, in combination with other drugs, are
rapid acting, potent antimalarials. As a single agent, artemesinin
therapy fails in a significant portion of patients (de Vries andDien,
1996). Recrudescent parasites remain susceptible to artemesi-
nin, which has given rise to the concept that there may be a
population of dormant parasites that can survive treatment. In
culture, a similar phenomenon can be recapitulated: a population
of early-stage parasites appears to be able to survive treatment
and grow back (Teuscher et al., 2010). In contrast to bacterial
persisters, the number of ‘‘dormant’’ parasites diminishes with
increasing concentrations of drug. The dormancy phenomenon
looks likely to be an important biological phenomenon, but one
simpler explanation has not yet been clearly ruled out. If arteme-
sinin kills with a shallow dose-response slope similar to that seen
for some anti-HIV drugs (Shen et al., 2008), not all the parasites
will be killed even at a dose high above the IC50 (see HIV section
below, Figure 4D).
New Strategies
The malaria parasite has managed to counter everything man
has thrown at it. There is an urgent need for new approaches.
One strategy is resistance reversal (Guantai and Chibale,
2010). A variety of compounds, most notably calcium channel
blockers such as verapamil, are able to restore chloroquine
efficacy against chloroquine-resistant parasites. This is thought
to be a direct effect on PfCRT (Martin et al., 2009). Further
development of such agents would benefit from a better under-
standing of the physiology and molecular details of the PfCRT-
drug interaction, which will be challenging for this large
membrane protein.
Another approach similar to that used against HIV-1 reverse
transcriptase (RT) is to combine two agents that work on the
same enzyme. DHFR mutants that are resistant to pyrimeth-
amine are more sensitive to the compound WR99210 and vice
versa, due to conflicting requirements for accommodation in
the active site (Mu¨ller and Hyde, 2010). It is difficult for a parasite
to become resistant to both compounds at the same time. A
similar concept is operative in certain HIV-1 drug combinations
for which resistance to one drug confers hypersusceptibility to
another (Sarafianos et al., 2004). Of course, one could conceive
of a parasite with a DHFR gene duplication in which one copy
confers resistance to one drug and the second confers resis-
tance to the other drug. Given the enormous genomic plasticity
of Plasmodium, such a scenario unfortunately becomes quite
feasible. Unfortunately, constructing a complex three- to four-
drug regimen, such as those used for TB and HIV-1, is currently
a pipe dream formalaria, as we do not have enough newdrugs to
begin to construct such a regimen.
Another strategy would be to force intraerythrocytic parasites
to differentiate into sexual forms en masse. This would halt
parasite multiplication in the bloodstream. Patients would
have to be kept away from mosquitoes until the parasites
were cleared from the circulation, to prevent transmission. If
resistance were to develop, it would hopefully impair differenti-
ation, resulting in dead-end parasites. A better understanding
of the physiological triggers of gametocytogenesis (Bousema1276 Cell 148, March 16, 2012 ª2012 Elsevier Inc.and Drakeley, 2011) would facilitate embarking on such an
approach.
A final strategy is to target parasites in the mosquito (Slavic
et al., 2011). The various life-cycle forms in the insect vector
range in population size from single digits (oocysts) to a few
thousand (sporozoites). This is many orders of magnitude less
than the number of parasites in the human bloodstream. There-
fore the probability of resistance is greatly reduced. One chal-
lenge is that a drug that worked on an insect stage would need
to be maintained at significant levels in the mosquito (mosquito
PK!) as well as in the human, and another issue is that the drug
is not likely to be curative for the patient with malaria. This
so-called transmission-blocking drug would be effective on
a population level and would need to be combined with intraer-
ythrocytic parasite-active agents for treatment.
For now, wemust keep producing new agents to stay ahead of
the inexorable development of resistance. People have been
developing antimalarial chemotherapy for centuries. Some of
the most successful efforts have stemmed from ethnobotany.
The ancient Chinese herbal remedy for fever emergencies, Qing-
hao, was developed into the potent antimalarial artemesinin
through an elegant extraction/identification project (Tu, 2011).
The ancient Peruvian fever remedy from the bark of the Cinchona
tree was used by the Jesuits as an antimalarial and later found to
have quinine as its active principle (Rocco, 2004). Many other
antimalarials have stemmed from wartime development efforts
(Ockenhouse et al., 2005). Our best hope at present is the Medi-
cines for Malaria Venture (MMV), a public-private partnership
that functions as a virtual drug company. Though only a decade
old, several formulations have already progressed to registration
and are in clinical use. So although there is a threat that we will
run out of treatments for malaria, there is a chance that we can
keep ahead of this adaptable bug.
HIV-1
Twenty-five antiretroviral drugs from six classes have been
approved to treat HIV-1 infection (Figure 3). Typically they are
used in three-drug combinations (Panel on Antiretroviral Guide-
lines for Adults and Adolescents, 2009; Thompson et al., 2010).
As with the other major human pathogens discussed here, drug
resistance seriously complicates treatment (Clavel and Hance,
2004; Larder et al., 1989; Clark et al., 2007; Margeridon-Thermet
and Shafer, 2010). Combination therapy can halt viral replication
and reduce plasma HIV-1 levels to below the detection limit of
clinical assays (Gulick et al., 1997; Hammer et al., 1997; Perelson
et al., 1997). Treatment failure is typically associated with prob-
lemswith adherence and does not generally increasewith time in
the patients who achieve an undetectable viral load (Boyd,
2009). However, resistance can occur for all six classes of anti-
retroviral drugs. Multidrug-resistant HIV-1 can arise when muta-
tions accumulate on the same viral genome (Palmer et al., 2005).
Although multidrug treatment failure is becoming less common
as regimens improve, it remains a serious problem with high
mortality (Deeks et al., 2009). For each drug, a stereotypical
set of mutations arise de novo in each failing patient. Resistant
viruses can also be transmitted (Little et al., 2002; Wheeler
et al., 2010), and among patients with newly diagnosed infection,
as many as 16% have drug-resistant HIV-1 in some areas
Figure 3. HIV-1 Life Cycle
HIV-1 attaches to CD4 via envelope protein spikes
on the surface of the virion. The CD4 interaction
triggers a conformational change in the envelope
protein that allows binding to a chemokine
receptor, CCR5 or CXCR4. This is followed by
further rearrangements of the envelope proteins
that mediate fusion of the viral envelope and the
cell membrane. The genomic viral RNA is then
copied by RT to give double-stranded viral DNA
that can be inserted into host cell DNA by in-
tegrase. Following transcription and translation,
viral proteins and genomic viral RNA assemble
into virions. During or shortly after release from the
virus-producing cell, viral polyproteins are cleaved
by HIV-1 protease into functional units, allowing
infection of additional cells. Entry can be blocked
by the chemokine receptor antagonist (CRA)
maraviroc (MVC) or by the fusion inhibitor enfu-
virtide (ENF). Reverse transcription is blocked by
the NRTIs lamivudine (3TC), abacavir (ABC),
zidovudine (AZT), stavudine (d4T), didanosine
(DDI), emtricitabine (FTC), and tenofovir disoproxil
fumarate (TDF) and by the NNRTIs efavirenz (EFV),
nevirapine (NVP), etravirine (ETR), and rilpivirine
(RPV). Integration is blocked by the integrase
strand transfer inhibitors raltegravir (RAL) and el-
vitegravir (ELV). Virus maturation is blocked by the
PIs amprenavir (APV), atazanavir (ATV), darunavir
(DRV), indinavir (IDV), lopinavir (LPV), nelfinavir
(NFV), saquinavir (SQV), and tipranavir (TPV).(Wheeler et al., 2010). Because of the rapid rate of HIV-1 evolu-
tion, the evolutionary dynamics of drug resistance have been
studied quantitatively, revealing interesting similarities and
differences with the other pathogens discussed here (Table 1).
Most of the principles derived from the study of HIV-1 drug resis-
tance apply to infection with the related but less pathogenic virus
HIV-2, which is largely restricted to West Africa and declining in
incidence (Ntemgwa et al., 2009).
Antiretroviral drugs target virus entry and the three virally en-
coded enzymes: protease, RT, and integrase (Figure 3). With
the exception of the chemokine receptor antagonists (CRAs),
which bind a host protein involved in entry, antiretroviral drugs
target virally encoded structures. Mutations in the viral genome
appearing in response to specific drugs are well defined
(summarized in Shafer, 2002; Clark et al., 2007; Johnson et al.,
2010), and the molecular mechanisms by which these mutations
confer resistance are understood (Acosta-Hoyos and Scott,
2010; Krishnan et al., 2010; Lobritz et al., 2010; Margeridon-
Thermet and Shafer, 2010; Sarafianos et al., 2004; Wensing
et al., 2010). Most resistance mutations interfere with drug
binding. The protease inhibitors (PIs) and nucleoside RT inhibi-
tors (NRTIs) are substrate analogs. Mutations conferring
resistance to these drugs allow the target enzyme to better
discriminate between the drug and the natural substrate.
However, other types of resistance involve unexpected adapta-
tions that permit viral replication in the presence of inhibitory
drugs. Resistance to CRAs involves either mutations in the viral
envelope protein that allow it to interact with the drug-bound
form of the chemokine receptor or the selection of viral variants
that utilize a different chemokine receptor for entry (Lobritz et al.,2010). The NRTIs are chain terminators lacking a 30 hydroxyl
group. Resistance to the thymidine analog zidovudine (AZT)
results from mutations that create a binding site on RT for ATP,
the b and g phosphates of which are positioned to function like
pyrophosphate in an excision reaction that is the reverse of the
reaction that incorporates the chain terminator (Acosta-Hoyos
and Scott, 2010; Sarafianos et al., 2004). This remarkable adap-
tation can be viewed as the evolution of a new enzymatic activity
that reverses drug inhibition.
When resistance develops, a change in treatment is indicated
(Panel on Antiretroviral Guidelines for Adults and Adolescents,
2009; Thompson et al., 2010). However, the choice of alternative
regimens is complicated by cross-resistance within drug
classes, increased toxicity of second-line agents, and, in many
areas of the world, limited availability of additional drugs. Two
types of resistance testing facilitate the choice of ‘‘salvage’’ regi-
mens. Bulk sequencing of plasma virus is commonly used to
detect mutations associated with resistance, and when multiple
mutations are present, physicians can utilize a more expensive
analysis in which the drug susceptibility of patient-derived viral
variants is directly assessed (Larder et al., 1989; Petropoulos
et al., 2000). Resistance testing is less available in resource-
limited settings.
Resistance was originally considered an inevitable conse-
quence of antiretroviral therapy. However, it has become clear
that resistance is largely avoidable with good adherence to
modern regimens. Success in preventing resistance reflects
dramatic advances in the effectiveness and tolerability of antire-
troviral drugs and improved understanding of the fundamental
biology underlying the evolution of resistance.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1277
Box 1. Insights into the Evolution of HIV-1 Drug Resistance Have
Come from a Mathematical Model of Viral Dynamics
(Panel A adapted from Wodarz and Nowak, 2002.) This model, origi-
nally developed by Martin Nowak and Alan Perelson (Ho et al., 1995;
Perelson et al., 1997; Wei et al., 1995; Wodarz and Nowak, 2002),
has three components: uninfected cells (x), free virus (v), and infected
cells (y). New uninfected cells are generated at a constant rate. Free
virus is produced at a rate that depends on the number of infected
cells (y) and a rate constant (k). Infected cells are generated through
the interaction of uninfected cells and free virus at a rate that depends
on concentration of each and a rate constant b. For each of these
components, decay is assumed to be exponential with characteristic
rate constants d, u, and a for uninfected cells, free virus, and infected
cells, respectively. R0, the number of newly infected cells that arise
from the virions produced by a single infected cell under conditions
where target cells are not limiting, is given by the expression lbk/dua
(Wodarz and Nowak, 2002). Resistance mutations can reduce b.
Antiretroviral drugs block new infection of susceptible cells without
affecting release of virus particles from previously infected cells.
Thus the drugs affect b but not k. In the case of effective HAART,
they reduce b to 0 such that virus production comes only from cells
infected prior to therapy. Viremia decays at a rate dependent on the
decay rates of free virus and various populations of virus-producing
cells. Analysis of the initial phase of decay has allowed measurement
of the decay rates u and a. Two phases of decay reflect the presence
of more stable populations of infected cells (panel B).
During the asymptomatic phase of the infection, plasma virus levels
are roughly constant in the absence of therapy. In this quasi-steady
state, virus production equals virus clearance, as described in the
fundamental equation of viral dynamics, ky = uv. This equation
provides a way to estimate the total body number of productively in-
fected cells (y) from a readily measured quantity, the level of plasma
virus (v). The virus production rate k can be estimated using measure-
ments of the burst size (N = k/a) and the decay rate of productively
infected cells (a). Assuming a burst size of 2,200, in the middle of
published estimates, the steady-state number of productively infected
cells for a patient with a typical plasma HIV-1 RNA level of 30,000
copies/ml and an extracellular fluid volume of 15 l is approximately
2 3 106. Given that average life span of most of the productively
infected cells (1/a) is only 1 day, this is also the number of newly
Box 1. Continued
infected cells that arise per day. This estimate of the number of newly
infected cells arising per day is lower than initial estimates of 109 that
were based on erroneous assumptions about the rate of increase in
CD4+ T cell counts following initiation of treatment. Nevertheless it is
large enough to guarantee that most single mutants pre-exist in the
average untreated patient. The total body number of infected cells
with a particular mutation can be calculated by (m/s)*y, where m is
the mutation rate and s is the selective disadvantage conferred
by the mutation. Although the precise values will depend on the
nucleotide substitution involved, values >1 are obtained even for
mutations with a high fitness cost because of the relationship between
the mutation rate and the population size.
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The capacity for rapid evolution is a critical characteristic of
HIV-1 that explains its ability to persist in the face of host immune
responses. The rapid evolution of HIV-1 is generally attributed to
the high error rate of RT and rapid replication rate of the virus.
Following entry of the virus into a CD4+ T cell, the 9.7 kB RNA
genome is reverse transcribed into double-stranded DNA by
RT. Base substitutions are introduced during reverse tran-
scription, and the resulting mutant viral genomes provide the
substrate for the evolution of resistance. The base substitution
rate is 2.4 3 105 substitutions/base pair/cycle (Mansky and
Temin, 1995). This mutation rate allows the virus to diversify
from what is usually a single infecting genome to an increasingly
complex set of related viruses (quasispecies) that coevolve over
time in each infected individual (Keele et al., 2008; Shankarappa
et al., 1999).
Although the RT error rate is substantially higher than the error
rate of host DNA polymerases, only one in four newly infected
cells should contain a substituted viral genome. It is the large
size and rapid turnover rate of the infected cell population,
coupled with the high error rate of RT, that give HIV-1 the
capacity for rapid evolution (Bonhoeffer and Nowak, 1997;
Coffin, 1995; Ho et al., 1995; Nowak et al., 1997; Wei et al.,
1995). The size of the infected cell population in the average
untreated patient is large enough so that at any given time every
possible single point mutant in the entire viral genome is likely to
pre-exist in some infected cell (Box 1). Pre-existing resistant
viruses can cause rapid treatment failure under certain condi-
tions described below.
The evolutionary dynamics of HIV-1 drug resistance are
complex (Coffin, 1995; Wei et al., 1995; Wodarz and Nowak,
2002) but are well understood in two situations. The first is the
case in which a single substitution gives rise to a variant that is
highly resistant to a given drug but still reasonably fit. Resistance
is typically evaluated as a fold change in the IC50, reflecting a shift
in the drug’s dose-response curve to the right (Figure 4A).
However, most resistance mutations reduce viral fitness in the
absence of drug (Quin˜ones-Mateu and Arts, 2001), and this
decrease in fitness must also be considered. Therefore, it is
useful to consider the basic reproductive ratios (R0) for wild-
type and mutant viruses (Figure 4B). R0 values > 1 are necessary
for spreading infection. An R0 value of 20 has been measured in
acute HIV-1 infection (Little et al., 1999). Most resistance
Figure 4. Dose-Response Curves for Anti-
retroviral Drugs
(A) Standard dose-response curve for a hypothet-
ical antiretroviral drug. The fraction of infection
events unaffected (fu) by the drug is plotted as
a function of the log of the drug concentration (log
D) for wild-type (WT) virus and a resistant mutant
(mut). In this example, the IC50 for wild-type virus is
0.01 mM, and the clinical concentration range is
1–10 mM (pink shaded box). The slope of the dose
response curve is 1. The resistance mutation is
assumed to increase the IC50 by 100-fold without
affecting the slope. The dotted lines indicate the
IC50 values for wild-type and mutant viruses.
(B) Dose-response curve for the viruses shown in
(A) with the reproductive ratio R0 as a measure of
infection. The resistance mutation is assumed to
cause a 50% decrease in fitness. The dotted lines
indicate the IC50 values for wild-type and mutant
viruses. The gray line indicates an R0 value of 1.
(C) Log-log plot of the dose-response curve
shown in (B). The gray line indicates an R0 value
of 1.
(D) Effect of slope. Log-log plot of the dose-
response curves for two drugs with the same
IC50 (0.01 mM) and m values of 1 (blue curve) and
3.5 (green curve). Note that the y axis scale is
expanded to capture the profound inhibitory
effects achieved with a high slope value. The gray
line indicates an R0 value of 1.
(E) Effect of a single resistance mutation on inhi-
bition by drug with highm. The drug is assumed to have an IC50 of 0.01 uM and a slope of 3.5. A resistance mutations increases the IC50 by 3-fold, reduces the
slope by one-third, and decreases fitness in the absence of drug by one-half. Nevertheless, R0 for the mutant virus remains well below 1 throughout the clinical
concentration range.
(F) Changes in slope can affect resistance. In this example, a drug inhibits both WT and mutant virus with the same IC50 (0.1 mM). The mutation causes a 50%
reduction in fitness but also reduces the slope from 1 to 0.5. Because there is no change in the IC50, standard methods of analysis would not classify the relevant
mutation as a resistance mutation. However, in the clinical concentration range, the mutation does cause resistance due to the change in slope.mutations cause some alteration in the function of the relevant
viral protein so as to reduce R0 in the absence of drug. The
dose-response curves for inhibition of wild-type and mutant
viruses cross at a particular drug concentration (Figures 4B
and 4C). Below this concentration, the fitness cost of the muta-
tion outweighs the benefit provided by resistance. Above that
concentration, the mutant has a selective advantage. Whether
pre-existing drug-resistant variants will grow out depends on
where the clinical concentration range of the drug lies in relation
to this crossover point. In situations where a single substitution
produces a variant that has a selective advantage at clinical
drug concentrations and R0 > 1, resistance can emerge very
rapidly in patients receiving monotherapy with that drug.
The scenario described above represents the simplest case
of the evolution of resistance and is illustrated by several impor-
tant clinical examples. Monotherapy with the NRTI lamivudine
(Schuurman et al., 1995), the non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) nevirapine (Wei et al., 1995), and the fusion
inhibitor enfuvirtide (Lobritz et al., 2010) all select for resistant
virus in a few weeks. Plasma virus levels fall initially after the initi-
ation of therapy but rise again as the resistant variants comes to
dominate the actively replicating virus population (Wei et al.,
1995). Perhaps the most dramatic example comes from studies
of mother-to-child transmission of HIV-1 in resource-limited
settings. Transmission can be reduced by administration of a
single dose of nevirapine to the mother at the time of delivery
and a single dose to the infant (Guay et al., 1999). However, as
a result of that single dose, the majority of the mothers developnevirapine-resistant virus that persists for months (Flys et al.,
2007).
Drug Efficacy and Resistance
Monotherapy does not always lead to immediate failure and
resistance. Although combination therapy regimens typically
produce better results in clinical trials, monotherapy with certain
PIs can suppress replication in a substantial fraction of patients
(Bierman et al., 2009). To understand this finding, we need to
consider differences in the intrinsic antiviral activity of different
drugs. Antiretroviral drug activity is typically expressed in terms
of the IC50. However, the drugs are used clinically at concentra-
tions substantially above the IC50, and inhibition at clinical
concentrations can only be predicted from the IC50 if the shape
of the dose-response curve is known. The shape is influenced
by cooperative interactions and is described mathematically by
the slope parameter or Hill coefficient (m). Recent studies have
shown that certain classesof antiretroviral drugs, notablyNNRTIs
and PIs, have cooperative dose-response curves with high
slopes even though they target enzymes that are univalent with
respect to the inhibitor (Shen et al., 2008; Jilek et al., 2012). These
high slopesmay reflect a unique form of intermolecular coopera-
tivity operative when multiple copies of a drug target participate
in a given step in the virus life cycle (Shen et al., 2011).
High slopes allow for extraordinarily high-level inhibition at
concentrations above IC50 because m has an exponential rela-
tionship to drug effect (Shen et al., 2008; Jilek et al., 2012). The
number of logs of inhibition of single-round infection events
produced by clinical concentrations of a drug or regimen isCell 148, March 16, 2012 ª2012 Elsevier Inc. 1279
called the instantaneous inhibitory potential or IIP. Figure 4D
compares the dose-response curves against wild-type virus of
two drugs with the same IC50 but different values of the slope
parameter and hence different IIPs. High slope values are the
major factor in the high IIP values of NNRTIs and PIs and likely
explain the great clinical utility of these two classes (Shen
et al., 2008; Jilek et al., 2012). Most combination therapy regi-
mens include an NNRTI or a PI (Panel on Antiretroviral Guidelines
for Adults and Adolescents, 2009; Thompson et al., 2010). The
highest IIP values are observed for PIs, and the ability of some
PI monotherapy regimens to suppress viremia in a substantial
fraction of patients is likely a reflection of the fact that these
drugs retain sufficient inhibitory potential against the single
mutants to reduce R0 to below 1 (Figure 4E).
The other situation in which the evolutionary dynamics of
HIV-1 drug resistance are straightforward is the case of effective
combination antiretroviral therapy. There is strong evidence that
ongoing viral replication is essentially halted in adherent patients
on modern regimens. Without replication, the evolution of resis-
tance cannot proceed. Clinically, evidence that combination
therapy can halt the evolution of resistance comes from the
outcomes of patients who remain adherent to current highly
active antiretroviral therapy (HAART) regimens. In these patients,
treatment failure and resistance are unusual (Boyd, 2009). In
most clinical trials, upwards of 80% of patients achieve and
maintain suppression of viremia to clinically undetectable levels.
How then does failure of combination therapy occur? Most of
the current thinking points to problems with adherence (Bangs-
berg et al., 2006; Paterson et al., 2000; Sethi et al., 2003). Subop-
timal adherence leads to drug levels that are insufficient to
reduce R0 to below 1. Additional replication allows the accumu-
lation of mutations that reduce the fitness cost of pre-existing
resistance mutations and confer resistance to additional drugs,
ultimately leading to a situation where the resistant virus has
an R0 value > 1 even in the presence of optimal drug concentra-
tions. The development of resistance and treatment failure are
associated with intermediate levels of adherence that allow
replication and the selection of resistant variants.
When resistance develops, the choice of salvage regimens
can be guided by resistance testing (Panel on Antiretroviral
Guidelines for Adults and Adolescents, 2009; Thompson et al.,
2010). However, a recent study suggests that the pharmacody-
namics of HIV-1 drug resistance may be considerably more
complex than previously appreciated (Sampah et al., 2011).
Current algorithms for determining the extent of resistance
caused by particular mutations are based exclusively on analysis
of changes in the IC50. This approach is based on the implicit
assumption that resistance mutations simply shift the dose-
response curve to the right without affecting the shape or slope
of the dose-response curve (Figures 4A–4C). However, most
resistance mutations also affect the dose-response curve slope.
Thus, as is shown in Figure 4F, the extent of resistance may be
underestimated if this critical variable is ignored.
Future Directions for HIV-1 Drugs
The introduction of new classes of antiretroviral drugs such as
entry inhibitors and integrase inhibitors has had a major impact
on HIV-1 treatment by allowing the construction of effective
salvage regimens for patients who develop resistance to the RT1280 Cell 148, March 16, 2012 ª2012 Elsevier Inc.and protease inhibitors used in initial treatment regimens.
Rational drugdesignbasedonknowledgeabout resistance toex-
isting drugs has provided second-generation RT, protease, and
integrase inhibitors that are effective against resistant viruses.
Improvements in regimen tolerability have led to a decrease in
the incidence of resistance. Although new drugs in existing
classes continue to be developed and new classes of drugs are
being explored, there is currently a critical need to extendexisting
treatment in resource-limitedsettingsand improve themonitoring
of therapy, which is critical to avoiding resistance.
Concluding Remarks
What we ultimately need is to develop better combinations that
can treat both drug-sensitive and drug-resistant organisms.
For TB, this means using new and existing compounds to
provide shorter, simpler, and less toxic regimens. For malaria,
this means coming up with an arsenal of new drugs for which
resistance has not yet taken hold. For HIV-1, we have drugs
that can stop virus replication and prevent the evolution of resis-
tance in adherent patients. Until a curative therapy is found, it will
be important to devise regimens that can be taken for the rest of
the patient’s life, with high adherence and low long-term toxicity,
and that can be made accessible to all infected individuals. The
rapid development of numerous drugs targeting different steps
in the HIV-1 life cycle, which when used together can control
the replication and prevent drug resistance in this rapidly
evolving pathogen, is likely to be a model for drug development
for all pathogens. The relative simplicity of the organism and
ease with which it can be studied in vitro undoubtedly contrib-
uted to this success. However, HIV-1 has been the subject of
an intense and well-funded research effort. A similar focus on
TB andmalaria might accelerate the development of new agents
to treat these important pathogens.
ACKNOWLEDGMENTS
This work was supported by the Howard Hughes Medical Institute and by
NIH grant AI081600 to R.F.S. Additional support came from the Einstein
CFAR Grant NIH AI51519. Thanks to Brian Weinrick, Pradip Rathod, and
Dhinakaran Samdbandan for their helpful discussions and suggestions.
REFERENCES
Acosta-Hoyos, A.J., and Scott, W.A. (2010). The role of nucleotide excision by
reverse transcriptase in HIV drug resistance. Viruses 2, 372–394.
Adams, K.N., Takaki, K., Connolly, L.E., Wiedenhoft, H., Winglee, K., Humbert,
O., Edelstein, P.H., Cosma, C.L., and Ramakrishnan, L. (2011). Drug tolerance
in replicating mycobacteria mediated by a macrophage-induced efflux mech-
anism. Cell 145, 39–53.
Ahmad, Z., Makaya, N.H., and Grosset, J. (2011). In Antituberculosis Chemo-
therapy, Volume 40, P.R. Donald, P.D. Helden, and C.T. Bolliger, eds. (Basel,
NY: S. Karger Pub), pp. 1–8.
Almeida, D., Nuermberger, E., Tasneen, R., Rosenthal, I., Tyagi, S., Williams,
K., Peloquin, C., and Grosset, J. (2009). Paradoxical effect of isoniazid on
the activity of rifampin-pyrazinamide combination in a mouse model of tuber-
culosis. Antimicrob. Agents Chemother. 53, 4178–4184.
Anderson, T.J., Patel, J., and Ferdig, M.T. (2009). Gene copy number and
malaria biology. Trends Parasitol. 25, 336–343.
Andrews, J.R., Gandhi, N.R., Moodley, P., Shah, N.S., Bohlken, L., Moll, A.P.,
Pillay, M., Friedland, G., and Sturm, A.W.; Tugela Ferry Care and Research
Collaboration. (2008). Exogenous reinfection as a cause of multidrug-resistant
and extensively drug-resistant tuberculosis in rural South Africa. J. Infect. Dis.
198, 1582–1589.
Andries, K., Verhasselt, P., Guillemont, J., Go¨hlmann, H.W., Neefs, J.M.,
Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005).
A diarylquinoline drug active on the ATP synthase of Mycobacterium tubercu-
losis. Science 307, 223–227.
Bangsberg, D.R., Acosta, E.P., Gupta, R., Guzman, D., Riley, E.D., Harrigan,
P.R., Parkin, N., and Deeks, S.G. (2006). Adherence-resistance relationships
for protease and non-nucleoside reverse transcriptase inhibitors explained
by virological fitness. AIDS 20, 223–231.
Bierman, W.F., van Agtmael, M.A., Nijhuis, M., Danner, S.A., and Boucher,
C.A. (2009). HIV monotherapy with ritonavir-boosted protease inhibitors:
a systematic review. AIDS 23, 279–291.
BMRC. (1948). STREPTOMYCIN treatment of pulmonary tuberculosis. BMJ 2,
769–782.
BMRC. (1950). TREATMENT of pulmonary tuberculosis with streptomycin and
para-aminosalicylic acid; a Medical Research Council investigation. BMJ 2,
1073–1085.
BMRC. (1952). TREATMENT of pulmonary tuberculosis with isoniazid; an
interim report to the Medical Research Council by their Tuberculosis Chemo-
therapy Trials Committee. BMJ 2, 735–746.
Bonhoeffer, S., and Nowak,M.A. (1997). Pre-existence and emergence of drug
resistance in HIV-1 infection. Proc. Biol. Sci. 264, 631–637.
Bousema, T., and Drakeley, C. (2011). Epidemiology and infectivity of Plasmo-
dium falciparum and Plasmodium vivax gametocytes in relation to malaria
control and elimination. Clin. Microbiol. Rev. 24, 377–410.
Boyd, M.A. (2009). Improvements in antiretroviral therapy outcomes over
calendar time. Curr. Opin. HIV AIDS 4, 194–199.
Bray, P.G., Martin, R.E., Tilley, L., Ward, S.A., Kirk, K., and Fidock, D.A. (2005).
Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance.
Mol. Microbiol. 56, 323–333.
Centers for Disease Control and Prevention (CDC). (1996). Clinical update:
impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis
patients with rifampin. MMWR Morb. Mortal. Wkly. Rep. 45, 921–925.
Clark, S., Calef, C., and Mellors, J. (2007). Mutations in retroviral genes
associated with drug resistance. In HIV Sequence Compendium, T. Leitner,
B. Foley, B. Hahn, P. Marx, F. McCutchan, J. Mellors, S. Wolinsky, and B.
Korber, eds. (Los Alamos, NM: Theoretical Biology and Biophysics Group,
Los Alamos National Laboratory), pp. 58–158.
Clavel, F., and Hance, A.J. (2004). HIV drug resistance. N. Engl. J. Med. 350,
1023–1035.
Coffin, J.M. (1995). HIV population dynamics in vivo: implications for genetic
variation, pathogenesis, and therapy. Science 267, 483–489.
Cooper, R.A., Ferdig, M.T., Su, X.Z., Ursos, L.M., Mu, J., Nomura, T., Fujioka,
H., Fidock, D.A., Roepe, P.D., and Wellems, T.E. (2002). Alternative mutations
at position 76 of the vacuolar transmembrane protein PfCRT are associated
with chloroquine resistance and unique stereospecific quinine and quinidine
responses in Plasmodium falciparum. Mol. Pharmacol. 61, 35–42.
Darwin, K.H., Ehrt, S., Gutierrez-Ramos, J.C., Weich, N., and Nathan, C.F.
(2003). The proteasome of Mycobacterium tuberculosis is required for resis-
tance to nitric oxide. Science 302, 1963–1966.
Deeks, S.G., Gange, S.J., Kitahata, M.M., Saag, M.S., Justice, A.C., Hogg,
R.S., Eron, J.J., Brooks, J.T., Rourke, S.B., Gill, M.J., et al. (2009). Trends in
multidrug treatment failure and subsequent mortality among antiretroviral
therapy-experienced patients with HIV infection in North America. Clin. Infect.
Dis. 49, 1582–1590.
de Vries, P.J., and Dien, T.K. (1996). Clinical pharmacology and therapeutic
potential of artemisinin and its derivatives in the treatment of malaria. Drugs
52, 818–836.
Dickinson, J.M., Aber, V.R., and Mitchison, D.A. (1977). Bactericidal activity of
streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and incombination against Mycobacterium Tuberculosis. Am. Rev. Respir. Dis. 116,
627–635.
Dondorp, A.M., Nosten, F., Yi, P., Das, D., Phyo, A.P., Tarning, J., Lwin, K.M.,
Ariey, F., Hanpithakpong, W., Lee, S.J., et al. (2009). Artemisinin resistance in
Plasmodium falciparum malaria. N. Engl. J. Med. 361, 455–467.
Dunner, E., Brown, W.B., and Wallace, J. (1949). The effect of streptomycin
with para-amino salicylic acid on the emergence of resistant strains of tubercle
bacilli. Dis. Chest 16, 661–666.
EA/BMRC. (1972). Controlled clinical trial of short-course (6-month) regimens
of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1, 1079–
1085.
Fidock, D.A., Nomura, T., Talley, A.K., Cooper, R.A., Dzekunov, S.M., Ferdig,
M.T., Ursos, L.M., Sidhu, A.B., Naude´, B., Deitsch, K.W., et al. (2000). Muta-
tions in the P. falciparum digestive vacuole transmembrane protein PfCRT
and evidence for their role in chloroquine resistance. Mol. Cell 6, 861–871.
Flys, T.S., Donnell, D., Mwatha, A., Nakabiito, C., Musoke, P., Mmiro, F.,
Jackson, J.B., Guay, L.A., and Eshleman, S.H. (2007). Persistence of
K103N-containing HIV-1 variants after single-dose nevirapine for prevention
of HIV-1 mother-to-child transmission. J. Infect. Dis. 195, 711–715.
Ford, C.B., Lin, P.L., Chase, M.R., Shah, R.R., Iartchouk, O., Galagan, J.,
Mohaideen, N., Ioerger, T.R., Sacchettini, J.C., Lipsitch, M., et al. (2011).
Use of whole genome sequencing to estimate the mutation rate of Mycobac-
terium tuberculosis during latent infection. Nat. Genet. 43, 482–486.
Gandhi, N.R., Nunn, P., Dheda, K., Schaaf, H.S., Zignol, M., van Soolingen, D.,
Jensen, P., and Bayona, J. (2010). Multidrug-resistant and extensively
drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet
375, 1830–1843.
Gandotra, S., Schnappinger, D., Monteleone, M., Hillen, W., and Ehrt, S.
(2007). In vivo gene silencing identifies the Mycobacterium tuberculosis
proteasome as essential for the bacteria to persist in mice. Nat. Med. 13,
1515–1520.
Gil, O., Dı´az, I., Vilaplana, C., Tapia, G., Dı´az, J., Fort, M., Ca´ceres, N., Pinto, S.,
Cayla`, J., Corner, L., et al. (2010). Granuloma encapsulation is a key factor for
containing tuberculosis infection in minipigs. PLoS ONE 5, e10030.
Gill, W.P., Harik, N.S., Whiddon, M.R., Liao, R.P., Mittler, J.E., and Sherman,
D.R. (2009). A replication clock for Mycobacterium tuberculosis. Nat. Med.
15, 211–214.
Ginsberg, A. (2011). The TBAlliance: overcoming challenges to chart the future
course of TB drug development. Future Med Chem 3, 1247–1252.
Grosset, J., Truffot-Pernot, C., Lacroix, C., and Ji, B. (1992). Antagonism
between isoniazid and the combination pyrazinamide-rifampin against tuber-
culosis infection in mice. Antimicrob. Agents Chemother. 36, 548–551.
Guantai, E., and Chibale, K. (2010). Chloroquine resistance: proposed mech-
anisms and countermeasures. Curr. Drug Deliv. 7, 312–323.
Guay, L.A., Musoke, P., Fleming, T., Bagenda, D., Allen, M., Nakabiito, C.,
Sherman, J., Bakaki, P., Ducar, C., Deseyve, M., et al. (1999). Intrapartum
and neonatal single-dose nevirapine compared with zidovudine for prevention
of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012
randomised trial. Lancet 354, 795–802.
Gulick, R.M., Mellors, J.W., Havlir, D., Eron, J.J., Gonzalez, C., McMahon, D.,
Richman, D.D., Valentine, F.T., Jonas, L., Meibohm, A., et al. (1997). Treatment
with indinavir, zidovudine, and lamivudine in adults with human immunodefi-
ciency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337,
734–739.
Hammer, S.M., Squires, K.E., Hughes, M.D., Grimes, J.M., Demeter, L.M.,
Currier, J.S., Eron, J.J., Jr., Feinberg, J.E., Balfour, H.H., Jr., Deyton, L.R.,
et al. (1997). A controlled trial of two nucleoside analogues plus indinavir in
persons with human immunodeficiency virus infection and CD4 cell counts
of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study
Team. N. Engl. J. Med. 337, 725–733.
Harrington, W.E., Mutabingwa, T.K., Muehlenbachs, A., Sorensen, B., Bolla,
M.C., Fried, M., and Duffy, P.E. (2009). Competitive facilitation ofCell 148, March 16, 2012 ª2012 Elsevier Inc. 1281
drug-resistant Plasmodium falciparum malaria parasites in pregnant women
who receive preventive treatment. Proc. Natl. Acad. Sci. USA 106, 9027–9032.
Hinshaw, H.C., Feldman, W.H., and Pfuetze, K.H. (1946). Treatment of tuber-
culosis with streptomycin; a summary of observations on one hundred cases.
J. Am. Med. Assoc. 132, 778–782.
Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., and
Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes
in HIV-1 infection. Nature 373, 123–126.
Hyde, J.E. (2005). Drug-resistant malaria. Trends Parasitol. 21, 494–498.
Istvan, E.S., Dharia, N.V., Bopp, S.E., Gluzman, I., Winzeler, E.A., and
Goldberg, D.E. (2011). Validation of isoleucine utilization targets in Plasmo-
dium falciparum. Proc. Natl. Acad. Sci. USA 108, 1627–1632.
Jilek, B.L., Zarr, M., Sampah, M., Rabi, S.A., Bullen, C.K., Lai, J., Shen, L., and
Siliciano, R.F. (2012). A quantitative basis for antiretroviral therapy for HIV-1
infection. Nat. Med. Published online February 19 2012. 10.1038/nm.2649.
Johnson, R., Streicher, E.M., Louw, G.E., Warren, R.M., van Helden, P.D., and
Victor, T.C. (2006). Drug resistance in Mycobacterium tuberculosis. Curr.
Issues Mol. Biol. 8, 97–111.
Johnson, V.A., Brun-Ve´zinet, F., Clotet, B., Gu¨nthard, H.F., Kuritzkes, D.R.,
Pillay, D., Schapiro, J.M., and Richman, D.D. (2010). Update of the drug resis-
tance mutations in HIV-1: December 2010. Top. HIV Med. 18, 156–163.
Kaneko, T., Cooper, C., and Mdluli, K. (2011). Challenges and opportunities in
developing novel drugs for TB. Future Med Chem 3, 1373–1400.
Keele, B.F., Giorgi, E.E., Salazar-Gonzalez, J.F., Decker, J.M., Pham, K.T.,
Salazar, M.G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008). Identification
and characterization of transmitted and early founder virus envelopes in
primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 105, 7552–7557.
Koenderink, J.B., Kavishe, R.A., Rijpma, S.R., and Russel, F.G. (2010). The
ABCs of multidrug resistance in malaria. Trends Parasitol. 26, 440–446.
Koul, A., Vranckx, L., Dendouga, N., Balemans, W., Van den Wyngaert, I.,
Vergauwen, K., Go¨hlmann, H.W., Willebrords, R., Poncelet, A., Guillemont,
J., et al. (2008). Diarylquinolines are bactericidal for dormant mycobacteria
as a result of disturbed ATP homeostasis. J. Biol. Chem. 283, 25273–25280.
Krishnan, L., Li, X., Naraharisetty, H.L., Hare, S., Cherepanov, P., and
Engelman, A. (2010). Structure-based modeling of the functional HIV-1
intasome and its inhibition. Proc. Natl. Acad. Sci. USA 107, 15910–15915.
Larder, B.A., Darby, G., and Richman, D.D. (1989). HIV with reduced sensitivity
to zidovudine (AZT) isolated during prolonged therapy. Science 243, 1731–
1734.
Laufer, M.K., Thesing, P.C., Eddington, N.D., Masonga, R., Dzinjalamala, F.K.,
Takala, S.L., Taylor, T.E., and Plowe, C.V. (2006). Return of chloroquine anti-
malarial efficacy in Malawi. N. Engl. J. Med. 355, 1959–1966.
Lehmann, J. (1946). Para-aminosalicylic acid in the treatment of tuberculosis.
Lancet 1, 15.
Little, S.J., McLean, A.R., Spina, C.A., Richman, D.D., and Havlir, D.V. (1999).
Viral dynamics of acute HIV-1 infection. J. Exp. Med. 190, 841–850.
Little, S.J., Holte, S., Routy, J.P., Daar, E.S., Markowitz, M., Collier, A.C., Koup,
R.A., Mellors, J.W., Connick, E., Conway, B., et al. (2002). Antiretroviral-drug
resistance among patients recently infected with HIV. N. Engl. J. Med. 347,
385–394.
Lin, G., Li, D., de Carvalho, L.P., Deng, H., Tao, H., Vogt, G., Wu, K., Schneider,
J., Chidawanyika, T., Warren, J.D., et al. (2009). Inhibitors selective for myco-
bacterial versus human proteasomes. Nature 461, 621–626.
Lobritz, M.A., Ratcliff, A.N., and Arts, E.J. (2010). HIV entry, inhibitors, and
resistance. Viruses 2, 1069–1105.
Mansky, L.M., and Temin, H.M. (1995). Lower in vivo mutation rate of human
immunodeficiency virus type 1 than that predicted from the fidelity of purified
reverse transcriptase. J. Virol. 69, 5087–5094.
Margeridon-Thermet, S., and Shafer, R.W. (2010). Comparison of the mecha-
nisms of drug resistance among HIV, hepatitis B, and hepatitis C. Viruses 2,
2696–2739.1282 Cell 148, March 16, 2012 ª2012 Elsevier Inc.Martin, R.E., Marchetti, R.V., Cowan, A.I., Howitt, S.M., Bro¨er, S., and Kirk, K.
(2009). Chloroquine transport via the malaria parasite’s chloroquine resistance
transporter. Science 325, 1680–1682.
Mathys, V., Wintjens, R., Lefevre, P., Bertout, J., Singhal, A., Kiass, M.,
Kurepina, N., Wang, X.M., Mathema, B., Baulard, A., et al. (2009). Molecular
genetics of para-aminosalicylic acid resistance in clinical isolates and sponta-
neous mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemo-
ther. 53, 2100–2109.
McCune, R.M., Jr., and Tompsett, R. (1956). Fate of Mycobacterium tubercu-
losis in mouse tissues as determined by the microbial enumeration technique.
I. The persistence of drug-susceptible tubercle bacilli in the tissues despite
prolonged antimicrobial therapy. J. Exp. Med. 104, 737–762.
McCune, R.M., Jr., McDermott, W., and Tompsett, R. (1956). The fate of
Mycobacterium tuberculosis in mouse tissues as determined by the microbial
enumeration technique. II. The conversion of tuberculous infection to the latent
state by the administration of pyrazinamide and a companion drug. J. Exp.
Med. 104, 763–802.
McCune, R.M., Feldmann, F.M., Lambert, H.P., and McDermott, W. (1966).
Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization
in mouse tissues. J. Exp. Med. 123, 445–468.
Mu¨ller, I.B., and Hyde, J.E. (2010). Antimalarial drugs: modes of action and
mechanisms of parasite resistance. Future Microbiol. 5, 1857–1873.
Nomura, T., Carlton, J.M., Baird, J.K., del Portillo, H.A., Fryauff, D.J., Rathore,
D., Fidock, D.A., Su, X., Collins, W.E., McCutchan, T.F., et al. (2001). Evidence
for different mechanisms of chloroquine resistance in 2 Plasmodium species
that cause human malaria. J. Infect. Dis. 183, 1653–1661.
Nowak, M.A., Lloyd, A.L., Vasquez, G.M., Wiltrout, T.A., Wahl, L.M., Bischof-
berger, N., Williams, J., Kinter, A., Fauci, A.S., Hirsch, V.M., and Lifson, J.D.
(1997). Viral dynamics of primary viremia and antiretroviral therapy in simian
immunodeficiency virus infection. J. Virol. 71, 7518–7525.
Ntemgwa, M.L., d’Aquin Toni, T., Brenner, B.G., Camacho, R.J., and
Wainberg, M.A. (2009). Antiretroviral drug resistance in human immunodefi-
ciency virus type 2. Antimicrob. Agents Chemother. 53, 3611–3619.
Ockenhouse, C.F., Magill, A., Smith, D., andMilhous, W. (2005). History of U.S.
military contributions to the study of malaria. Mil. Med. 170 (Suppl 4), 12–16.
Palmer, S., Kearney, M., Maldarelli, F., Halvas, E.K., Bixby, C.J., Bazmi, H.,
Rock, D., Falloon, J., Davey, R.T., Jr., Dewar, R.L., et al. (2005). Multiple, linked
human immunodeficiency virus type 1 drug resistance mutations in treatment-
experienced patients are missed by standard genotype analysis. J. Clin. Mi-
crobiol. 43, 406–413.
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2009). Guide-
lines for the use of antiretroviral agents in HIV-1-infected adults and adoles-
cents. Department of Health and Human Services. Available at http://www.
Aidsinfo.Nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 1–161.
Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., Squier, C.,
Wagener, M.M., and Singh, N. (2000). Adherence to protease inhibitor therapy
and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21–30.
Payne, D. (1987). Spread of chloroquine resistance in Plasmodium falciparum.
Parasitol. Today (Regul. Ed.) 3, 241–246.
Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K.,
Markowitz, M., and Ho, D.D. (1997). Decay characteristics of HIV-1-infected
compartments during combination therapy. Nature 387, 188–191.
Petropoulos, C.J., Parkin, N.T., Limoli, K.L., Lie, Y.S., Wrin, T., Huang,W., Tian,
H., Smith, D., Winslow, G.A., Capon, D.J., and Whitcomb, J.M. (2000). A novel
phenotypic drug susceptibility assay for human immunodeficiency virus type
1. Antimicrob. Agents Chemother. 44, 920–928.
Pichugin, A.V., Yan, B.S., Sloutsky, A., Kobzik, L., and Kramnik, I. (2009).
Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas
during chronic tuberculosis infection and reactivation in genetically resistant
hosts. Am. J. Pathol. 174, 2190–2201.
Quin˜ones-Mateu, M.E., and Arts, E.J. (2001). In HIV-1 Fitness: Implications for
Drug Resistance, Disease Progression, and Global Epidemic Evolution, C.
Kuiken, B. Foley, B. Hahn, P. Marx, F. McCutchan, J.W. Mellors, S. Wolinsky,
and B. Korber, eds. (Los Alamos, NM: Theoretical Biology and Biophysics
Group, Los Alamos National Laboratory), pp. 134–170.
Rathod, P.K. (1997). Antimalarial agents directed at thymidylate synthase. J.
Pharm. Pharmacol. 49, 65–69.
Rocco, F. (2004). The Miraculous Fever-Tree: The Cure that Changed the
World (San Francisco, CA: Harper Collins).
Roper, C., Pearce, R., Bredenkamp, B., Gumede, J., Drakeley, C., Mosha, F.,
Chandramohan, D., and Sharp, B. (2003). Antifolate antimalarial resistance in
southeast Africa: a population-based analysis. Lancet 361, 1174–1181.
Sambandamurthy, V.K., Wang, X., Chen, B., Russell, R.G., Derrick, S., Collins,
F.M., Morris, S.L., and Jacobs, W.R., Jr. (2002). A pantothenate auxotroph of
Mycobacterium tuberculosis is highly attenuated and protects mice against
tuberculosis. Nat. Med. 8, 1171–1174.
Sampah, M.E., Shen, L., Jilek, B.L., and Siliciano, R.F. (2011). Dose-response
curve slope is a missing dimension in the analysis of HIV-1 drug resistance.
Proc. Natl. Acad. Sci. USA 108, 7613–7618.
Sarafianos, S.G., Das, K., Hughes, S.H., and Arnold, E. (2004). Taking aim at
a moving target: designing drugs to inhibit drug-resistant HIV-1 reverse tran-
scriptases. Curr. Opin. Struct. Biol. 14, 716–730.
Schatz, A., and Waksman, S. (1944). Streptomycin, a substance exhibiting
antibiotic activity against Gram-positive and Gram-negative bacteria. Proc.
Soc. Exp. Biol. Med. 55, 66–69.
Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis,
P., Danner, S.A., Mulder, J., Loveday, C., Christopherson, C., et al. (1995).
Rapid changes in human immunodeficiency virus type 1RNA load and appear-
ance of drug-resistant virus populations in persons treated with lamivudine
(3TC). J. Infect. Dis. 171, 1411–1419.
Sethi, A.K., Celentano, D.D., Gange, S.J., Moore, R.D., and Gallant, J.E.
(2003). Association between adherence to antiretroviral therapy and human
immunodeficiency virus drug resistance. Clin. Infect. Dis. 37, 1112–1118.
Shafer, R.W. (2002). Genotypic testing for human immunodeficiency virus type
1 drug resistance. Clin. Microbiol. Rev. 15, 247–277.
Shankarappa, R., Margolick, J.B., Gange, S.J., Rodrigo, A.G., Upchurch, D.,
Farzadegan, H., Gupta, P., Rinaldo, C.R., Learn, G.H., He, X., et al. (1999).
Consistent viral evolutionary changes associated with the progression of
human immunodeficiency virus type 1 infection. J. Virol. 73, 10489–10502.
Shen, L., Peterson, S., Sedaghat, A.R., McMahon, M.A., Callender, M., Zhang,
H., Zhou, Y., Pitt, E., Anderson, K.S., Acosta, E.P., and Siliciano, R.F. (2008).
Dose-response curve slope sets class-specific limits on inhibitory potential
of anti-HIV drugs. Nat. Med. 14, 762–766.
Shen, L., Rabi, S.A., Sedaghat, A.R., Shan, L., Lai, J., Xing, S., and Siliciano,
R.F. (2011). A critical subset model provides a conceptual basis for the high
antiviral activity of major HIV drugs. Sci. Transl. Med. 3, 91ra63.
Shi, W., Zhang, X., Jiang, X., Yuan, H., Lee, J.S., Barry, C.E., 3rd, Wang, H.,
Zhang, W., and Zhang, Y. (2011). Pyrazinamide inhibits trans-translation in
Mycobacterium tuberculosis. Science 333, 1630–1632.
Slavic, K., Delves, M.J., Prudeˆncio, M., Talman, A.M., Straschil, U., Derby-
shire, E.T., Xu, Z., Sinden, R.E., Mota, M.M., Morin, C., et al. (2011). Use of
a selective inhibitor to define the chemotherapeutic potential of the plasmodial
hexose transporter in different stages of the parasite’s life cycle. Antimicrob.
Agents Chemother. 55, 2824–2830.
Spigelman, M.K. (2007). New tuberculosis therapeutics: a growing pipeline. J.
Infect. Dis. 196 (Suppl 1), S28–S34.
Sreevatsan, S., Stockbauer, K.E., Pan, X., Kreiswirth, B.N., Moghazeh, S.L.,
Jacobs, W.R., Jr., Telenti, A., and Musser, J.M. (1997). Ethambutol resistance
in Mycobacterium tuberculosis: critical role of embB mutations. Antimicrob.
Agents Chemother. 41, 1677–1681.
Srivastava, S., Musuka, S., Sherman, C., Meek, C., Leff, R., and Gumbo, T.
(2010). Efflux-pump-derivedmultiple drug resistance to ethambutolmonother-
apy in Mycobacterium tuberculosis and the pharmacokinetics and pharmaco-
dynamics of ethambutol. J. Infect. Dis. 201, 1225–1231.
Srivastava, S., Sherman, C., Meek, C., Leff, R., and Gumbo, T. (2011).
Pharmacokinetic mismatch does not lead to emergence of isoniazid- orrifampin-resistant Mycobacterium tuberculosis but to better antimicrobial
effect: a new paradigm for antituberculosis drug scheduling. Antimicrob.
Agents Chemother. 55, 5085–5089.
Sweany, H.C., Turner, G.C., Lichtenstein, M., and Entin, S. (1949). A prelimi-
nary report on the use of para-amino salicylic acid in the treatment of pulmo-
nary tuberculosis. Dis. Chest 16, 633–660, illust.
Takayama, K., and Kilburn, J.O. (1989). Inhibition of synthesis of arabinogalac-
tan by ethambutol in Mycobacterium smegmatis. Antimicrob. Agents Chemo-
ther. 33, 1493–1499.
Teuscher, F., Gatton, M.L., Chen, N., Peters, J., Kyle, D.E., and Cheng, Q.
(2010). Artemisinin-induced dormancy in plasmodium falciparum: duration,
recovery rates, and implications in treatment failure. J. Infect. Dis. 202,
1362–1368.
Thomas, J.P., Baughn, C.O., Wilkinson, R.G., and Shepherd, R.G. (1961).
A new synthetic compound with antituberculous activity in mice: ethambutol
(dextro-2,20-(ethylenediimino)-di-l-butanol). Am.Rev.Respir. Dis.83, 891–893.
Thompson, M.A., Aberg, J.A., Cahn, P., Montaner, J.S., Rizzardini, G., Telenti,
A., Gatell, J.M., Gu¨nthard, H.F., Hammer, S.M., Hirsch, M.S., et al; Interna-
tional AIDS Society-USA. (2010). Antiretroviral treatment of adult HIV infection:
2010 recommendations of the International AIDS Society-USA panel. JAMA
304, 321–333.
Tu, Y. (2011). The discovery of artemisinin (qinghaosu) and gifts from Chinese
medicine. Nat. Med. 17, 1217–1220.
Vaidya, A.B., andMather, M.W. (2000). Atovaquone resistance inmalaria para-
sites. Drug Resist. Updat. 3, 283–287.
Vilche`ze, C., and Jacobs, W.R., Jr. (2007). The mechanism of isoniazid killing:
clarity through the scope of genetics. Annu. Rev. Microbiol. 61, 35–50.
Vilche`ze, C., Wang, F., Arai, M., Hazbo´n, M.H., Colangeli, R., Kremer, L.,
Weisbrod, T.R., Alland, D., Sacchettini, J.C., and Jacobs, W.R., Jr. (2006).
Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves
the target of isoniazid. Nat. Med. 12, 1027–1029.
Vinayak, S., Alam, M.T., Mixson-Hayden, T., McCollum, A.M., Sem, R., Shah,
N.K., Lim, P., Muth, S., Rogers, W.O., Fandeur, T., et al. (2010). Origin and
evolution of sulfadoxine resistant Plasmodium falciparum. PLoS Pathog. 6,
e1000830.
Wei, X.,Ghosh, S.K., Taylor,M.E., Johnson,V.A., Emini, E.A., Deutsch, P., Lifson,
J.D., Bonhoeffer, S., Nowak, M.A., Hahn, B.H., et al. (1995). Viral dynamics in
human immunodeficiency virus type 1 infection. Nature 373, 117–122.
Wensing, A.M., van Maarseveen, N.M., and Nijhuis, M. (2010). Fifteen years
of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res. 85,
59–74.
Wheeler, W.H., Ziebell, R.A., Zabina, H., Pieniazek, D., Prejean, J., Bodnar,
U.R., Mahle, K.C., Heneine, W., Johnson, J.A., and Hall, H.I.; Variant, Atypical,
and Resistant HIV Surveillance Group. (2010). Prevalence of transmitted drug
resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses,
U.S.-2006. AIDS 24, 1203–1212.
White, N.J. (2004). Antimalarial drug resistance. J. Clin. Invest. 113, 1084–
1092.
WHO. (2010). Multidrug and Extensively Drug-Resistant Tuberculosis: 2010
Global Report on Surveillance and Response (Geneva, Switzerland: World
Health Organization).
Wodarz, D., and Nowak, M.A. (2002). Mathematical models of HIV pathogen-
esis and treatment. Bioessays 24, 1178–1187.
Yeager, R.L., Munroe, W.G., and Dessau, F.I. (1952). Pyrazinamide (aldina-
mide) in the treatment of pulmonary tuberculosis. Am. Rev. Tuberc. 65,
523–546.
Zhang, M., Li, S.Y., Rosenthal, I.M., Almeida, D.V., Ahmad, Z., Converse, P.J.,
Peloquin, C.A., Nuermberger, E.L., and Grosset, J.H. (2011). Treatment of
tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Am. J. Respir. Crit. Care Med. 183, 1254–1261.
Zimhony, O., Cox, J.S., Welch, J.T., Vilche`ze, C., and Jacobs, W.R., Jr. (2000).
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of
Mycobacterium tuberculosis. Nat. Med. 6, 1043–1047.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1283
